On the basis of phase 2 studies, trastuzumab deruxtecan was approved for patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic gastric cancer or gastroesophageal ...

Trastuzumab deruxtecan plus pertuzumab significantly extends PFS compared to THP in HER2-positive metastatic breast cancer. The combination demonstrated a 44% lower risk of disease progression or ...

CHICAGO — Second-line trastuzumab deruxtecan-nxki significantly extended OS compared with paclitaxel plus ramucirumab for patients with advanced gastric cancers previously treated with ...

WILMINGTON, Del., June 02, 2025--Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically ...

Background: Trastuzumab-pertuzumab combined with taxanes or eribulin has emerged as a promising therapeutic regimen for HER2-positive breast cancer, a subtype known for its aggressive clinical course.

Background: Metastatic breast cancer, particularly that which expresses the HER2 receptor, poses a significant therapeutic challenge in oncology, often associated with an unfavorable prognosis.

SHANGHAI, May 29, 2025 /PRNewswire/ -- The National Medical Products Administration has recently granted approval for Trastuzumab rezetecan, China's first domestically developed antibody-drug ...

NU MOA's Carl Cholo Ahayao Melicor was the highest scorer with a 84.85% result, while two other NU MOA graduates—Jawaher Panda Aguam and Sharina Saliendra Uy—achieved the second and third highest ...

Purpose: The role of trastuzumab in adjuvant therapy for locally invasive breast cancer is discussed. Summary: Trastuzumab is a humanized monoclonal antibody that binds to the extracellular domain ...

A MEMORANDUM of agreement (MOA) that will allow companies to include minimum wage earners in the government's P20 per kilogram (kg) rice program has been drafted, the Department of Agriculture (DA) ...